Latest news with #385.00

Business Insider

Nuvama Sticks to Their Buy Rating for Jubilant Pharmova Limited (JUBLPHARMA)

In a report released yesterday, Shrikant Akolkar from Nuvama maintained a Buy rating on Jubilant Pharmova Limited (JUBLPHARMA – Research Report), with a price target of INR1,385.00. The company's shares closed yesterday at INR1,173.90. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Akolkar is a 2-star analyst with an average return of -2.3% and a 0.00% success rate. Akolkar covers the Healthcare sector, focusing on stocks such as Aurobindo Pharma Ltd, Cipla Ltd, and Jubilant Pharmova Limited. The word on The Street in general, suggests a Hold analyst consensus rating for Jubilant Pharmova Limited. Based on Jubilant Pharmova Limited's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR19.29 billion and a net profit of INR1.54 billion. In comparison, last year the company earned a revenue of INR17.59 billion and had a GAAP net loss of INR586 million